Search for content, post, videos

Further positive trial results from Ultimovacs

Ultimovacs lab
Ultimovacs has announced positive results from the second cohort of 10 patients after one year of its ongoing US-based Phase I clinical trial. The clinical trial evaluates the company's universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treat
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.